AI Drug Discovery: New Cancer Drug Family Developed
- Oxford Drug Design, a company linked to the University of Oxford, announced a critically important breakthrough in the development of a potential new cancer therapy.
- The therapy, which researchers believe could be effective against various types of tumors, has successfully completed in vivo validation - a crucial step in determining the safety and...
- Researchers used genetically modified guinea pigs that replicate the early genetic mutations leading to colorectal cancer.
Oxford Drug Design Announces Promising AI-Driven Cancer Therapy
Oxford Drug Design, a company linked to the University of Oxford, announced a critically important breakthrough in the development of a potential new cancer therapy. Utilizing its proprietary GenAI platform, powered by artificial intelligence, the company has created a novel approach to fighting the disease.
The therapy, which researchers believe could be effective against various types of tumors, has successfully completed in vivo validation – a crucial step in determining the safety and efficacy of new drugs. This phase typically involves testing on animal models before human trials.
Researchers used genetically modified guinea pigs that replicate the early genetic mutations leading to colorectal cancer. They demonstrated statistically significant anti-tumor activity, with efficacy comparable to rapamycin, a commonly used cancer treatment.
Further details on the research can be found here and information on the role of artificial intelligence in cancer research is available here.